Allogeneic hemopoietic stem cell transplantation of matched unrelated donors carries an increased risk of graft versus host disease (GvHD) and transplant related mortality (TRM). We introduced ATG Fresenius at median dose of 90 mg/kg body weight as part of the conditioning regimen for prevention of serious GvHD. We compared 48 recipients of mismatched transplants with 170 recipients of an HLA-matched transplant. The mismatches involved one or two loci. The groups differed in age [HLA-matched: 33 years (0,9–61) HLA-mismatched: 21 years (0,9–51)] and graft source, bone marrow versus peripheral blood stem cell (matched 67% bone marrow, mismatched 83% bone marrow). They were comparable in diagnosis, stage of disease and conditioning. Key words: Mismatched unrelated donor, anti-thymocyte-globuline, stem cell transplantation
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this paper
Cite this paper
Zander, A.R. et al. (2008). Anti Thymocyte Globuline Allows for Successful Transplantation from HLA Mismatched Unrelated Donors. In: Bilko, N.M., Fehse, B., Ostertag, W., Stocking, C., Zander, A.R. (eds) Stem Cells and their Potential for Clinical Application. NATO Science for Peace and Security Series A: Chemistry and Biology. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-6469-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-4020-6469-2_21
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-6467-8
Online ISBN: 978-1-4020-6469-2
eBook Packages: MedicineMedicine (R0)